Can Total Liab vs Other Stockholder Equity Analysis

CANF Stock

USD 1.96 0.01 0.51%

Can Fite financial indicator trend analysis is way more than just evaluating Can Fite Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Can Fite Biopharma is a good investment. Please check the relationship between Can Fite Total Liab and its Other Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Total Liab vs Other Stockholder Equity

Total Liab vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Can Fite Biopharma Total Liab account and Other Stockholder Equity. At this time, the significance of the direction appears to have weak relationship.

The correlation between Can Fite's Total Liab and Other Stockholder Equity is 0.38. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Can Fite Biopharma, assuming nothing else is changed. The correlation between historical values of Can Fite's Total Liab and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Can Fite Biopharma are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Total Liab i.e., Can Fite's Total Liab and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.38

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Other Stockholder Equity

Most indicators from Can Fite's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Can Fite Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Can Fite's Sales General And Administrative To Revenue is most likely to decrease significantly in the upcoming years.

Can Fite fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Treasury Stock	Common Stock	Property Plant Equipment	Net Tangible Assets
Common Stock Shares Outstanding		0.28	0.09	0.13	0.32	0.29	0.42	0.18	-0.89	-0.37	-0.17	-0.19	0.81	0.31	-0.35	0.91	0.1	-0.09	0.74	0.13	0.94	0.28	0.02	0.96	0.59	-0.3
Total Assets	0.28		0.17	0.16	0.96	0.83	0.53	-0.56	-0.44	-0.31	0.57	-0.04	0.35	0.95	-0.2	0.4	0.78	0.0	0.28	0.73	0.29	1.0	0.58	0.42	0.51	0.04
Other Current Liab	0.09	0.17		0.34	0.04	0.3	-0.24	-0.07	-0.12	-0.49	0.07	0.0	-0.08	0.13	0.08	-0.03	0.37	0.27	0.15	0.44	0.02	0.17	0.15	0.04	-0.18	0.03
Total Current Liabilities	0.13	0.16	0.34		-0.02	0.17	0.26	0.36	-0.36	0.4	-0.36	0.28	0.29	-0.02	0.16	0.13	0.2	0.65	0.3	0.54	0.15	0.14	0.29	0.19	0.21	-0.47
Total Stockholder Equity	0.32	0.96	0.04	-0.02		0.73	0.56	-0.52	-0.41	-0.37	0.53	-0.16	0.36	0.97	-0.26	0.45	0.6	-0.19	0.23	0.51	0.32	0.97	0.48	0.46	0.57	0.2
Other Liab	0.29	0.83	0.3	0.17	0.73		0.39	-0.63	-0.43	-0.43	0.63	0.02	0.39	0.76	-0.16	0.37	0.81	0.1	0.43	0.76	0.3	0.82	0.51	0.36	0.47	-0.18
Property Plant And Equipment Net	0.42	0.53	-0.24	0.26	0.56	0.39		0.18	-0.6	-0.01	-0.17	0.15	0.77	0.48	-0.36	0.7	0.23	-0.04	0.36	0.29	0.44	0.51	0.14	0.65	0.93	-0.21
Net Debt	0.18	-0.56	-0.07	0.36	-0.52	-0.63	0.18		-0.18	0.39	-1.0	0.27	0.24	-0.61	0.19	0.16	-0.63	0.24	0.12	-0.41	0.18	-0.58	-0.42	0.2	0.16	-0.24
Retained Earnings	-0.89	-0.44	-0.12	-0.36	-0.41	-0.43	-0.6	-0.18		0.21	0.17	-0.1	-0.89	-0.36	0.2	-0.93	-0.34	-0.25	-0.84	-0.42	-0.82	-0.43	-0.36	-0.93	-0.67	0.5
Accounts Payable	-0.37	-0.31	-0.49	0.4	-0.37	-0.43	-0.01	0.39	0.21		-0.39	0.54	-0.13	-0.44	0.28	-0.35	-0.24	0.39	-0.2	-0.06	-0.27	-0.34	0.02	-0.34	-0.15	-0.28
Cash	-0.17	0.57	0.07	-0.36	0.53	0.63	-0.17	-1.0	0.17	-0.39		-0.27	-0.23	0.62	-0.19	-0.15	0.64	-0.24	-0.11	0.42	-0.17	0.58	0.42	-0.19	-0.15	0.24
Non Current Assets Total	-0.19	-0.04	0.0	0.28	-0.16	0.02	0.15	0.27	-0.1	0.54	-0.27		0.15	-0.28	0.36	-0.11	0.22	0.65	0.13	0.29	-0.08	-0.11	0.25	-0.14	0.04	-0.4
Other Assets	0.81	0.35	-0.08	0.29	0.36	0.39	0.77	0.24	-0.89	-0.13	-0.23	0.15		0.29	-0.43	0.93	0.17	0.1	0.71	0.26	0.82	0.33	0.19	0.89	0.84	-0.41
Cash And Short Term Investments	0.31	0.95	0.13	-0.02	0.97	0.76	0.48	-0.61	-0.36	-0.44	0.62	-0.28	0.29		-0.37	0.41	0.66	-0.28	0.21	0.56	0.28	0.97	0.44	0.43	0.5	0.22
Net Receivables	-0.35	-0.2	0.08	0.16	-0.26	-0.16	-0.36	0.19	0.2	0.28	-0.19	0.36	-0.43	-0.37		-0.41	0.0	0.64	-0.11	0.06	-0.35	-0.22	0.1	-0.4	-0.42	-0.32
Common Stock Total Equity	0.91	0.4	-0.03	0.13	0.45	0.37	0.7	0.16	-0.93	-0.35	-0.15	-0.11	0.93	0.41	-0.41		0.17	-0.07	0.72	0.19	0.85	0.4	0.16	0.97	0.79	-0.32
Non Current Liabilities Total	0.1	0.78	0.37	0.2	0.6	0.81	0.23	-0.63	-0.34	-0.24	0.64	0.22	0.17	0.66	0.0	0.17		0.32	0.31	0.93	0.1	0.76	0.62	0.16	0.17	-0.28
Other Current Assets	-0.09	0.0	0.27	0.65	-0.19	0.1	-0.04	0.24	-0.25	0.39	-0.24	0.65	0.1	-0.28	0.64	-0.07	0.32		0.26	0.51	-0.04	-0.04	0.48	-0.09	-0.12	-0.62
Other Stockholder Equity	0.74	0.28	0.15	0.3	0.23	0.43	0.36	0.12	-0.84	-0.2	-0.11	0.13	0.71	0.21	-0.11	0.72	0.31	0.26		0.38	0.62	0.27	0.42	0.74	0.54	-0.57
Total Liab	0.13	0.73	0.44	0.54	0.51	0.76	0.29	-0.41	-0.42	-0.06	0.42	0.29	0.26	0.56	0.06	0.19	0.93	0.51	0.38		0.14	0.71	0.64	0.21	0.22	-0.42
Property Plant And Equipment Gross	0.94	0.29	0.02	0.15	0.32	0.3	0.44	0.18	-0.82	-0.27	-0.17	-0.08	0.82	0.28	-0.35	0.85	0.1	-0.04	0.62	0.14		0.28	-0.07	0.89	0.62	-0.31
Total Current Assets	0.28	1.0	0.17	0.14	0.97	0.82	0.51	-0.58	-0.43	-0.34	0.58	-0.11	0.33	0.97	-0.22	0.4	0.76	-0.04	0.27	0.71	0.28		0.56	0.42	0.5	0.07
Treasury Stock	0.02	0.58	0.15	0.29	0.48	0.51	0.14	-0.42	-0.36	0.02	0.42	0.25	0.19	0.44	0.1	0.16	0.62	0.48	0.42	0.64	-0.07	0.56		0.11	0.09	-0.14
Common Stock	0.96	0.42	0.04	0.19	0.46	0.36	0.65	0.2	-0.93	-0.34	-0.19	-0.14	0.89	0.43	-0.4	0.97	0.16	-0.09	0.74	0.21	0.89	0.42	0.11		0.76	-0.28
Property Plant Equipment	0.59	0.51	-0.18	0.21	0.57	0.47	0.93	0.16	-0.67	-0.15	-0.15	0.04	0.84	0.5	-0.42	0.79	0.17	-0.12	0.54	0.22	0.62	0.5	0.09	0.76		-0.24
Net Tangible Assets	-0.3	0.04	0.03	-0.47	0.2	-0.18	-0.21	-0.24	0.5	-0.28	0.24	-0.4	-0.41	0.22	-0.32	-0.32	-0.28	-0.62	-0.57	-0.42	-0.31	0.07	-0.14	-0.28	-0.24

Click cells to compare fundamentals

Can Fite Account Relationship Matchups

Can Fite fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	286.4K	358.4M	553.1M	815.7M	1.3B	1.3B
Total Assets	8.2M	9.5M	20.3M	9.3M	10.0M	10.5M
Other Current Liab	610K	288K	852K	727K	944K	891.4K
Total Current Liabilities	3.3M	1.3M	2.7M	2.5M	2.0M	2.4M
Total Stockholder Equity	2.4M	6.1M	14.4M	4.5M	6.2M	5.6M
Other Liab	2.4M	2.2M	3.1M	2.3M	2.6M	2.0M
Property Plant And Equipment Net	118K	123K	185K	126K	81K	87.2K
Net Debt	(2.6M)	(8.2M)	(4.3M)	(2.9M)	(4.2M)	(4.4M)
Retained Earnings	(110.3M)	(125.5M)	(140.7M)	(150.8M)	(158.5M)	(166.4M)
Accounts Payable	2.2M	561K	954K	896K	427K	833.0K
Cash	2.7M	8.3M	4.4M	3.0M	4.3M	4.6M
Non Current Assets Total	1.0M	123K	185K	126K	81K	77.0K
Cash And Short Term Investments	2.8M	8.3M	19.1M	8.0M	8.9M	8.4M
Net Receivables	651K	18K	48K	47K	78K	74.1K
Common Stock Total Equity	2.4M	2.6M	8.2M	33.0M	38.0M	39.9M
Liabilities And Stockholders Equity	8.2M	9.5M	20.3M	9.3M	10.0M	10.5M
Non Current Liabilities Total	2.5M	2.2M	3.1M	2.3M	1.7M	2.4M
Other Current Assets	3.7M	1.0M	881K	1.1M	986K	1.6M
Other Stockholder Equity	103.4M	97.4M	93.3M	154.2M	163.6M	106.5M
Total Liab	5.7M	3.4M	5.9M	4.8M	3.7M	4.8M
Property Plant And Equipment Gross	119K	123K	185K	126K	344K	361.2K
Total Current Assets	7.1M	9.4M	20.1M	9.2M	9.9M	10.3M
Common Stock	2.6M	8.2M	33.0M	60.7M	69.8M	73.2M
Property Plant Equipment	118K	123K	185K	126K	144.9K	84.8K
Net Tangible Assets	2.4M	6.1M	14.4M	4.5M	4.0M	7.2M
Non Currrent Assets Other	912K	(123K)	(185K)	(126K)	(113.4K)	(107.7K)
Current Deferred Revenue	469K	334K	818K	783K	622K	594.8K
Net Invested Capital	877K	6.1M	14.4M	4.5M	6.2M	6.0M
Net Working Capital	3.9M	8.1M	17.3M	6.7M	7.9M	8.4M
Short Term Investments	64K	75K	14.7M	5.0M	4.6M	4.5M

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:

How To Invest In Can

Details

Is Can Stock a good investment?

Details

What is Can Fite's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.60)

Quarterly Revenue Growth

(0.19)

Return On Assets

(0.57)

Return On Equity

(1.58)

The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Can Total Liab vs Other Stockholder Equity Analysis

Total Liab vs Other Stockholder Equity

Total Liab vs Other Stockholder Equity Correlation Analysis

Correlation Coefficient

Total Liab

Other Stockholder Equity

Can Fite fundamental ratios Correlations

Can Fite Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Can Fite fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 0.97	Total Stockholder Equity
Total Current Assets	+ 0.97	Total Stockholder Equity
Total Current Assets	+ 0.97	Cash And Short Term Investments
Common Stock	+ 0.97	Common Stock Total Equity
Common Stock	+ 0.96	Common Stock Shares Outstanding

Cash	- 1.0	Net Debt
Common Stock	- 0.93	Retained Earnings
Common Stock Total Equity	- 0.93	Retained Earnings
Other Assets	- 0.89	Retained Earnings
Retained Earnings	- 0.89	Common Stock Shares Outstanding
Other Stockholder Equity	- 0.84	Retained Earnings